CDC Releases Report With "Shocking" Stats About New Vaccine

This vaccine, designed to offer enhanced protection against the prevailing coronavirus variants, was sanctioned by the U.S. Food and Drug Administration (FDA) on September 11, 2023.

The FDA announced, "The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was issued to Pfizer Inc.

October 15, 2023

The approval of Spikevax (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2023-2024 Formula) was issued to ModernaTX Inc."

 MUST WATCH: GIANT EMPEROR TRUMP FIGURE AT ITALIAN FESTIVAL

On the following day, the CDC recommended that all U.S. citizens above six months of age receive the updated COVID vaccine produced by Moderna and Pfizer-BioNTech. Echoing the CDC's recommendation, President Joe Biden urged, "I encourage all Americans to stay up-to-date on their vaccines."

 MUST WATCH: AUSTRALIAN BROADCASTER MOPS THE FLOOR WITH CLIMATE ACTIVISTS

The CDC further advised, "If you have not received a COVID-19 vaccine in the past 2 months, get an updated COVID-19 vaccine to protect yourself this fall and winter." Despite these governmental efforts, only about 2% of U.S. citizens have chosen to receive the new booster vaccine.

 UNIVERSITY OF WASHINGTON SET TO ESTABLISH "GAZA CAMP" AFTER BEING DENIED FOR LACK OF LEADERSHIP

The U.S. Department of Health and Human Services (HHS) disclosed that approximately 7 million Americans have received the latest updated COVID vaccine, which equates to roughly 2% of the U.S. population. CNN reported, "In comparison, when last year’s bivalent COVID-19 booster was available, more than 18 million people had received a dose by October 12, 2022, about six weeks after the CDC signed off on it, according to CDC data. By May, about 56.5 million people had received that booster, representing about 17% of the U.S. population."

 THE TRAGIC TALE OF IGNORED WARNINGS: HOW 2023 MAINE MASS SHOOTING COULD HAVE BEEN PREVENTED

The uptake of the booster shots is significantly lower compared to previous versions of the mRNA vaccine targeting COVID. CDC data shows that over 92% of U.S. adults received the first COVID vaccine rolled out in December 2020. The number of recipients for the second mRNA vaccine fell to 79%, and a scant 20% of Americans received the bivalent COVID booster.

 WAIT FOR GAS PRICES TO RISE! OVER 30 MISSILES LAUNCHED AT UKRAINE'S ENERGY INFRASTRUCTURE

An HHS spokesperson explained, "COVID-19 vaccine distribution, which has shifted to the private market, is a lot different than it was last year when the government was distributing them. The Biden-Harris Administration, through HHS, has been working directly with manufacturers and distributors to ensure that the vaccines are getting to pharmacies, hospitals, clinics, pediatricians, and other vaccination sites, including long-term care facilities."

 U.S. INTELLIGENCE AGENCIES' REPORT RELEASED: WHO WAS RESPONSIBLE FOR NAVALNY'S DEATH?

Despite the transition to private distribution, the HHS reported that nearly 14 million vaccines have already been delivered to pharmacies and other locations, and that "91% of Americans 12 years and older can access the vaccine within 5 miles of where they live."

 ARE ENTHUSIASTIC PRO-HAMAS ACTIVISTS SHIFTING LOYALTIES TO ANOTHER TERRORIST GROUP?

Most Americans can receive a free COVID-19 vaccine through health insurance, local health centers, and pharmacies participating in the CDC's Bridge Access Program.

On a related note, Pfizer announced on Friday that it would need to slash $3.5 billion in costs due to rapidly declining profits from COVID-19 products. "Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products," the statement read. "Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations."

 OSCAR PISTORIUS' SEEN FOR FIRST TIME SINCE PRISON RELEASE (EIGHT YEARS AGO!)

Pfizer disclosed that it has initiated a "multi-year, enterprise-wide cost realignment program that will realign its costs with its longer-term revenue expectations." The pharmaceutical giant expects these cost-cutting measures to save at least $3.5 billion – $1 billion in 2023 and $2.5 billion in 2024.